Ali Mohammed's questions to Vir Biotechnology Inc (VIR) leadership • Q4 2024
Question
Ali Mohammed from Leerink Partners asked about the potential for moving Vir's T-cell engagers into earlier lines of therapy given strong early signals. He also inquired how the company's machine learning and antibody engineering capabilities are being applied to optimize T-cell engager design.
Answer
Dr. Mark Eisner, CMO, confirmed interest in moving into earlier lines of therapy, particularly for the PSMA program, with more details to come. He also explained that Vir's dAIsY machine learning platform is being used to rapidly identify and optimize binders for the next generation of T-cell engagers. CEO Dr. Marianne De Backer added that their protein engineering platform uses a combination of internal and external models to quickly generate and test molecules with improved characteristics.